Michitaka Imai
AuthID: R-00K-HNA
1
TÃTULO: Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population Full Text
AUTORES: Casadei Gardini, Andrea; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; ...Mais
PUBLICAÇÃO: 2023, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 180
AUTORES: Casadei Gardini, Andrea; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; ...Mais
PUBLICAÇÃO: 2023, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 180
INDEXADO EM: Scopus WOS
2
TÃTULO: Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? Full Text
AUTORES: Rimini, Margherita; Persano, Mara; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Piscaglia, Fabio; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...Mais
PUBLICAÇÃO: 2023, FONTE: TARGETED ONCOLOGY
AUTORES: Rimini, Margherita; Persano, Mara; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Piscaglia, Fabio; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...Mais
PUBLICAÇÃO: 2023, FONTE: TARGETED ONCOLOGY
INDEXADO EM: Scopus WOS
3
TÃTULO: Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab Full Text
AUTORES: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa Ramos, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Stefanini, Bernardo; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...Mais
PUBLICAÇÃO: 2023, FONTE: ONCOLOGY, VOLUME: 101, NÚMERO: 5
AUTORES: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa Ramos, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Stefanini, Bernardo; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...Mais
PUBLICAÇÃO: 2023, FONTE: ONCOLOGY, VOLUME: 101, NÚMERO: 5
INDEXADO EM: Scopus WOS
4
TÃTULO: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients Full Text
AUTORES: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...Mais
PUBLICAÇÃO: 2023, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 189
AUTORES: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...Mais
PUBLICAÇÃO: 2023, FONTE: EUROPEAN JOURNAL OF CANCER, VOLUME: 189
INDEXADO EM: Scopus WOS
5
TÃTULO: α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma Full Text
AUTORES: Rossari, Federico; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Yoo, Changhoon; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Bergamo, Francesca; Amadeo, Elisabeth; Vitiello, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...Mais
PUBLICAÇÃO: 2023, FONTE: INTERNATIONAL JOURNAL OF CANCER
AUTORES: Rossari, Federico; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Yoo, Changhoon; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, Jose; Masi, Gianluca; Bergamo, Francesca; Amadeo, Elisabeth; Vitiello, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; ...Mais
PUBLICAÇÃO: 2023, FONTE: INTERNATIONAL JOURNAL OF CANCER
INDEXADO EM: Scopus WOS
6
TÃTULO: Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study Full Text
AUTORES: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; ...Mais
PUBLICAÇÃO: 2022, FONTE: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
AUTORES: Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Rimassa, Lorenza; Presa, Jose; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; ...Mais
PUBLICAÇÃO: 2022, FONTE: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
INDEXADO EM: Scopus WOS